Canaccord Genuity analyst Caitlin Cronin reiterated a Buy rating on AxoGen today and set a price target of $24.00. The company’s shares closed today at $17.87.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, REPRO-MED Systems, and InMode. According to TipRanks, Cronin has an average return of 4.3% and a 52.34% success rate on recommended stocks.
AxoGen has an analyst consensus of Strong Buy, with a price target consensus of $23.50, which is a 31.51% upside from current levels. In a report released yesterday, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $25.00 price target.
AXGN market cap is currently $794.2M and has a P/E ratio of -168.78.
Read More on AXGN:
Disclaimer & DisclosureReport an Issue
- AxoGen initiated with a Buy at H.C. Wainwright
- Optimistic Buy Rating for AxoGen Amid Regulatory Delays and Market Potential
- Keurig Dr Pepper buys JDE Peet’s, Thoma Bravo to acquire Verint: Morning Buzz
- FDA Extends Review for AxoGen’s Avance Nerve Graft
- AxoGen: FDA extends PDUFA date for BLA for Avance Nerve Graft to December 5
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
